No

Antiarrhythmic Agent, Class I-C

Ventricular arrhythmias; supraventricular arrhythmias

B

Hypersensitivity to encainide or any component; second or third degree A-V block; premature ventricular complexes; nonsustained ventricular arrhythmias; cardiogenic shock

>10%:

Central nervous system: Dizziness

Ocular: Blurred vision

1% to 10%:

Cardiovascular: Chest pain congestive heart failure, ventricular tachycardia

Central nervous system: Headache

Gastrointestinal: Vomiting

Neuromuscular & skeletal: Weakness

Otic: Tinnitus

CYP2D6 enzyme substrate; beta-blockers (possible negative inotropic effects)

Adults: Oral: 25 mg every 8 hours; may increase to 35 mg every 8 hours after 3-5 days if needed; increase to 50 mg every 8 hours in another 3-5 days if response is not achieved

Give around-the-clock rather than 4 times/day, 3 times/day, etc (ie, 12-6-12-6, not 9-1-5-9) to promote less variation in peak and trough serum levels

Dizziness is common

Use beta-blockers with caution; may produce additive negative inotropic effect; caution with TCAs

No information available to require special precautions

No effects or complications reported

Take as directed; do not change dose except from advice of your physician; report any chest pain and irregular heartbeats

Capsule, as hydrochloride: 25 mg, 35 mg, 50 mg